Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Medifast (MED) Net Income towards Common Stockholders (2016 - 2025)

Medifast's Net Income towards Common Stockholders history spans 16 years, with the latest figure at -$18.1 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 2437.42% year-over-year to -$18.1 million; the TTM value through Dec 2025 reached -$18.7 million, down 1003.73%, while the annual FY2025 figure was -$18.7 million, 994.68% down from the prior year.
  • Net Income towards Common Stockholders reached -$18.1 million in Q4 2025 per MED's latest filing, down from -$2.3 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $47.0 million in Q2 2021 to a low of -$18.1 million in Q4 2025.
  • Average Net Income towards Common Stockholders over 5 years is $19.5 million, with a median of $24.8 million recorded in 2022.
  • The largest YoY upside for Net Income towards Common Stockholders was 130.35% in 2025 against a maximum downside of 2437.42% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at $34.0 million in 2021, then dropped by 22.06% to $26.5 million in 2022, then plummeted by 77.24% to $6.0 million in 2023, then tumbled by 87.16% to $775000.0 in 2024, then plummeted by 2437.42% to -$18.1 million in 2025.
  • Per Business Quant, the three most recent readings for MED's Net Income towards Common Stockholders are -$18.1 million (Q4 2025), -$2.3 million (Q3 2025), and $2.5 million (Q2 2025).